ROJAY PASSLEY: Open Payments
NPI 1497321483 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$899 in 47 payments from 10 companies in 2025. Trend: 2023 $1,528 · 2024 $1,287 · 2025 $899
Food & beverage: $899
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 14 | $254 |
| Vanda Pharmaceuticals Inc. | 8 | $173 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $145 |
| ABBVIE INC. | 5 | $94 |
| Otsuka America Pharmaceutical, Inc. | 4 | $75 |
| Lundbeck LLC | 3 | $54 |
| Janssen Pharmaceuticals, Inc | 2 | $40 |
| Collegium Pharmaceutical, Inc. | 2 | $30 |
| Tris Pharma Inc | 1 | $18 |
| Noven Therapeutics, LLC | 1 | $16 |
Products named: FANAPT, CAPLYTA, LYBALVI, ARISTADA, REXULTI, VRAYLAR, ABILIFY ASIMTUFII, SPRAVATO.
Industry payments across NE — which companies pay providers there.
